Etanercept
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Etanercept: From Rheumatoid Arthritis to Rheumatoid Vasculitis
One-Sentence Summary
Etanercept is a TNF-α receptor fusion protein whose established use spans rheumatoid arthritis and related inflammatory arthritides. The TxGNN model predicts it may be effective for Rheumatoid Vasculitis, but the supporting evidence — 6 clinical trials and 20 publications — is dominated by case reports of etanercept-induced vasculitis and a negative Phase I/II trial in ANCA-associated vasculitis, making this a high-risk rather than a straightforwardly positive signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid Arthritis (established global indication; TFDA-specific approved label text is not on file — data gap) |
| Predicted New Indication | Rheumatoid Vasculitis |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L2 |
| US Market Status | Not Marketed (Taiwan) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (data gap DG002). Based on known information, etanercept is a soluble p75 TNF receptor–Fc fusion protein that neutralizes TNF-α; its efficacy in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis is well established.
Rheumatoid vasculitis is a severe extra-articular manifestation of rheumatoid arthritis, and TNF-α is implicated in vascular wall inflammation — which is the theoretical basis for the TxGNN prediction. However, this mechanistic plausibility is directly contradicted by the clinical evidence collected: the only dedicated Phase I/II RCT of etanercept in ANCA-associated vasculitis (Wegener’s granulomatosis, the WGET trial) failed to show benefit and raised a malignancy signal, and a substantial body of case reports and cohort data describe etanercept inducing cutaneous vasculitis, ANCA-associated vasculitis, and vasculitis-like/lupus-like events rather than treating them (e.g., BSRBR-RA cohort data on drug-induced vasculitis-like events).
In short, the “same mechanism, adjacent disease” logic that normally supports repurposing is undermined here by a documented paradoxical/adverse drug reaction, not merely a lack of data. This candidate should be treated as a safety-flagged hypothesis rather than a promising efficacy lead.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00001901 | Phase 1/2 | Completed | 60 | WGET trial of etanercept in Wegener’s granulomatosis (ANCA-associated vasculitis) — did not achieve improved remission rates and was associated with increased malignancy risk; the only direct efficacy trial, and it is negative |
| NCT05696106 | N/A | Unknown | 750,000 | Large real-world study of risk of new immune-mediated inflammatory disease in patients on biologics/immunosuppressants; safety-signal oriented, not efficacy |
| NCT01557322 | N/A | Completed | 1,754 | Real-world treatment pathways in moderate RA patients starting etanercept; not vasculitis-specific |
| NCT02590562 | N/A | Completed | 808 | Cross-sectional study of biologic DMARD treatment patterns in RA; indirectly relevant only |
| NCT01579006 | N/A | Completed | 184 | Non-interventional RA cohort on tocilizumab; indirectly relevant only |
| NCT07138898 | Phase 2 | Not yet recruiting | 80 | Perioperative immunosuppressant management in rheumatology patients undergoing shoulder arthroplasty; not disease-specific to vasculitis |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33058033 | 2021 | Systematic Review | Clinical Rheumatology | Systematic review of biological therapy in rheumatoid vasculitis; summarizes limited and heterogeneous evidence base |
| 28391344 | 2017 | Review | Nephrol Dial Transplant | Reviews the (limited, uncertain) role of TNF-α blockade in ANCA-associated vasculitis and glomerulonephritis |
| 28123776 | 2017 | Cohort | RMD Open | BSRBR-RA registry: TNF inhibitors, including etanercept, carry drug-specific risk of inducing lupus-like and vasculitis-like events in RA patients |
| 15468348 | 2004 | Review (safety signal) | J Rheumatology | Reviews TNF-α blockade and the risk of vasculitis as an adverse effect |
| 31632872 | 2019 | Case report | Cureus | Etanercept-associated nephropathy |
| 15853915 | 2005 | Case series (adverse event) | Scand J Immunology | Cutaneous vasculitis associated with both etanercept and infliximab |
| 12209493 | 2002 | Case report | Arthritis and Rheumatism | Accelerated nodulosis and vasculitis following etanercept therapy for RA |
| 11792895 | 2002 | Case report | Rheumatology (Oxford) | Etanercept and infliximab associated with cutaneous vasculitis |
| 25544845 | 2014 | Case report | Case Reports in Medicine | Large vessel vasculitis occurring in an RA patient under anti-TNF therapy |
| 15801034 | 2005 | Case report | J Rheumatology | Proliferative lupus nephritis and leukocytoclastic vasculitis during etanercept treatment |
US Market Information
Not marketed in Taiwan — no NDA/license records are on file (0 licenses registered).
Safety Considerations
Please refer to the package insert for safety information (key warnings, contraindications, and drug-interaction data are all marked as data gaps — DG001, Blocking severity — and DDI query returned no results).
Conclusion and Next Steps
Decision: Hold
Rationale:
- The only direct efficacy trial (WGET, Phase I/II in ANCA-associated vasculitis) was negative and flagged a malignancy risk, while multiple independent case reports and a large RA registry cohort document etanercept inducing cutaneous, renal, and large-vessel vasculitis rather than treating it — the safety signal actively works against this repurposing hypothesis.
To proceed, the following is needed:
- TFDA label warnings/contraindications and DDI data (currently a Blocking data gap, DG001) — required before any S1 safety evaluation can proceed
- Confirmed detailed MOA data from DrugBank (High-severity gap, DG002)
- A dedicated, adequately powered RCT specifically in rheumatoid vasculitis (not ANCA-vasculitis) showing a positive efficacy signal
- A structured pharmacovigilance/monitoring plan given the documented drug-induced vasculitis risk
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.